PHPaul Leslie Hofman

Paul Leslie Hofman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul Leslie Hofman has a total of 255 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gonadotropin-releasing hormone agonist therapy for catamenial seizures and stroke-like episodes in MELAS syndrome: two case reports

    by Elizabeth Stone, Rachael L. Sumner, Emma Glamuzina, Bryony Ryder, Paul L. Hofman, Cynthia Sharpe

    Introduction: Mitochondrial Encephalomyelopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS) is a progressive inherited mitochondrial disorder, characterised by recurrent stroke-like episodes (SLEs), epilepsy and stepwise neurological decline, caused by pathogenic variants in mitochondrial, and rarely, nuclear DNA. Seizures affect approximately 90% of patients and are considered a driver of SLEs. Catamenial worsening of seizures — typically defined as a ≥2-fold increase in seizure frequency or severity at specific phases of the menstrual cycle — has been described in approximately 40% of women with epilepsy but, to our knowledge, has not previously been reported in MELAS.Cases: We report two females with mtDNA-related MELAS (m.3243A>G and m.3252A>G) whose SLEs and seizures developed in the second decade of life and showed a clear perimenstrual (C1) pattern of exacerbation. Both were treated with depot leuprolide acetate (Lucrin) to suppress hypothalamic-pituitary-gonadal cycling, with continuous replacement transdermal sex-steroid. In both cases, GnRH-agonist therapy reduced seizure and SLE frequency, although clinical benefit was only apparent after pituitary down-regulation was complete (typically 2–3 months / two depot doses). Incomplete cycle suppression in one patient required dose escalation; in the other, oestrogen add-back was poorly tolerated and consistently worsened SLEs, with improvement when oestrogen was withdrawn.Conclusion: These cases demonstrate menstrual-cycle-linked exacerbation of epilepsy and SLEs in mtDNA-related MELAS and provide preliminary evidence that complete suppression of cyclic ovarian steroid production with a GnRH agonist can, at least temporarily, reduce disease burden. Despite initial benefit, both patients continued to deteriorate and died of progressive neurological disease.

  • Open Access

    Exploring User Experiences With the Lift App for Emotional Well-Being Among Youth With Type 1 Diabetes: Qualitative Study

    by Katie M Babbott, Kristin Harrison Ginsberg, Anna L Boggiss, Joanna McClintock, Chloe Hudson, Paul Hofman, Ryan Paul, Alana Cavadino, Hiran Thabrew, Craig Jefferies, et al.

    Background: Individuals living with type 1 diabetes (T1D) are at an increased risk of experiencing psychological distress; however, there remains a scarcity of scalable and widely accessible support services, particularly for adolescents and young adults. To address this gap, digital mental health interventions are becoming an increasingly important area of innovation in diabetes care. Objective: This study aimed to explore qualitative feedback regarding the “Lift: Thriving with Diabetes” ( Lift ) well-being app, designed to support emotional well-being among adolescents and young adults with T1D, which was recently tested in a 12-week feasibility trial conducted in New Zealand and the United States. Methods: Of the 59 adolescents and young adults and 22 support people who participated in the main Lift feasibility trial, 13 agreed to participate in this secondary qualitative study. Participants attended a virtual focus group or 1-on-1 interview to discuss their experiences using the app and to explore their perspectives on the app’s engagement, functionality, and perceived impact on well-being and diabetes-related coping. Transcribed audio recordings were analyzed using directed content analysis, guided by the Mobile Application Rating Scale end-user framework (with topics of engagement, functionality, aesthetics, and information quality) and interpreted from a realist theoretical position. Results: In total, 9 adolescents and young adults (mean age 21.5, SD 2.06 years; n=5, 56% men) and 4 support people (2 fathers, 1 friend, and 1 partner; mean age 31.3, SD 18.92 years; n=2, 50% men) completed interviews. Overall, participants viewed Lift as engaging, easy to use, and emotionally impactful. The most positive feedback focused on the app’s interactive features, particularly a well-being tree that “grew” with increased engagement, and its “calming” visual aesthetics. Users also reported meaningful emotional or behavioral impact, particularly in promoting connection, self-awareness, and practical coping strategies in living with T1D. However, user feedback also highlighted areas for improvement, including the need for improved content pacing, personalization, connection with other digital health tools, and greater gamification to sustain long-term engagement. Participants consistently expressed a desire for content tailored to their age, role (eg, support person vs young person), and personal preferences (eg, voice, pace, tone, and interactivity). Conclusions: Findings underscore the potential of user-driven, emotionally intelligent digital tools to enhance well-being and connection for young people with T1D, as well as their support people. These insights can inform the refinement of Lift and the development of broader digital health interventions aimed at promoting well-being and fostering meaningful, sustained impact.

  • Open Access

    21-Deoxycortisone: A Novel Sensitive and Specific Newborn Screening Marker for Congenital Adrenal Hyperplasia

    by Mark de Hora, Natasha Heather, Dianne Webster, Benjamin B. Albert, Paul Hofman

    21-deoxycortisol is a sensitive and specific blood marker for congenital adrenal hyperplasia (CAH). We postulated that 21-deoxycortisone, the 11β-hydroxysteroid dehydrogenase metabolite of 21-deoxycortisol, may also be an accurate bloodspot marker of CAH. Measurement of 21-deoxycortisone was performed on 42 residual NBS specimens with a true positive result for CAH, 11 with a false negative result, and 439 specimens with a false positive result. For this study, the test was considered positive if 21-deoxycortisone was detected. The sensitivity and specificity of 21-deoxycortisone as a marker for classical CAH was calculated and compared to 21-deoxycortisol data from a previous New Zealand study. The method for 21-deoxycortisone measurement was linear to 1000 nmol/L and precision was 7.3–10.3%. The lower limit of quantification was 2 nmol/L, and recovery was 99%. 21-deoxycortisone was ≥2 nmol/L in all 42 true positive samples and in 10 false negative samples, and was not detected in the false positive group of specimens. The sensitivity of 21-deoxycortisone was 98.1%, and specificity was 100%. In a previous study, the sensitivity of 21-deoxycortisol was 88.7% and specificity was 99.8% in 1910 newborn screening tests carried out between 2018 and 2021. Incorporating 21-deoxycortisone into a second-tier test and adjustment of primary screening protocols could improve the accuracy of newborn screening for CAH. Longer term prospective studies on the performance of 21-deoxycortisone are warranted.

  • Open Access

    21-Deoxycortisone: A Novel Sensitive and Specific Newborn Screening Marker for Congenital Adrenal Hyperplasia

    by Mark de Hora, Natasha Heather, Dianne Webster, Benjamin Albert, Paul L. Hofman

    Background: 21-deoxycortisol (21DF) is a sensitive and specific blood marker for congenital adrenal hyperplasia (CAH). We postulated that 21-deoxycortisone (21DE), the 11β-hydroxysteroid dehydrogenase metabolite of 21DF, may also be an accurate bloodspot marker of CAH.Method: Measurement of 21DE was performed on 42 residual NBS specimens with a true positive (TP) result for CAH, 11 with a false negative result (FN), and 441 specimens with a false positive result (FP). The test was considered positive if 21DE was detected. The sensitivity and specificity of 21DE as a marker for classical CAH was calculated and compared to 21DF data from a previous NZ study.Results: The method was linear to 1000nmol/L and precision was 7.3-10.3%. The lower limit of quantification was 2 nmol/L, recovery was 99%. 21DE was ≥2 nmol/L in all 42 TP samples and in 10 TN samples and was not detected in the FP group. Sensitivity was 98.1% and specificity was 100%.In a previous study, the sensitivity of 21DF was 88.7% and specificity was 99.8% in 1910 NBS tests carried out between 2018-2021.Conclusions: 21DE is a sensitive and specific marker for CAH in the newborn period. Incorporating 21DE into a second-tier test and adjustment of primary screening protocols could improve the accuracy of NBS for CAH. Longer term prospective studies on the performance of 21DE are warranted.

  • Open Access

    Seasonal variation in BMI outcomes at 6 months: secondary analyses of a multidisciplinary healthy lifestyle programme for children and adolescents with obesity

    by José G. B. Derraik, Kima T. Costelloe, Cervantée E. K. Wild, Lisa E. Wynter, Mohammad Shahbaz, Paul L. Hofman, Yvonne C. Anderson

    Background: While international evidence suggests seasonal variations may influence outcomes of interventions for pediatric obesity, data for Aotearoa New Zealand are limited. We examined seasonal variations in changes in body mass index standard deviation score (BMI SDS) in young people with obesity enrolled in an intervention programme. Methods: We studied 397 children and adolescents (median = 10.1 years; range 3.7–16.8 years) from Whānau Pakari, a multidisciplinary community-based healthy lifestyle programme (initially a randomised clinical trial that subsequently transitioned into the regional childhood obesity service). Participants were stratified by season at entry and 6-month BMI SDS changes (Δ) were evaluated. Lifestyle factors were also assessed. Data were analysed using traditional linear models and machine learning (random forest). Results: 68% of participants had BMI SDS reductions at 6 months (mean = − 0.16 SDS; P < 0.0001). Linear models showed seasonal variations in programme effectiveness, with BMI SDS reductions among summer (− 0.17 SDS), autumn (− 0.19 SDS) and winter (− 0.18 SDS) but not among spring entrants. Random forest modelling identified higher baseline BMI SDS and younger age as the most influential predictors of greater 6-month reductions in BMI SDS. Season of entry was more important than any single lifestyle factor; spring entrants exhibited attenuated reductions relative to other seasons. Conclusions: The season at programme entry was an important factor associated with intervention effectiveness. Spring entry was associated with attenuated BMI SDS reductions, likely due to the inclusion of the summer holidays within the 6-month intervention. These findings highlight the need for targeted support during such unstructured periods to improve participant outcomes. Graphical

  • Open Access

    Sex‐Specific BMI Trajectories in Young People With Type 1 Diabetes: A 20‐Year Retrospective Regional Audit

    by Connor Oliver-Rose, Lourdes M. Lagera, Aimee Cooper, Paul L. Hofman, José G. B. Derraik, Yvonne C. Anderson

    Background: The rates of obesity and type 1 diabetes (T1D) in children and adolescents are increasing in many settings worldwide, but data on weight gain in this group are limited in New Zealand. We examined temporal body mass index (BMI) changes and associated factors in young people with T1D in a mixed urban–rural region. Methods: This study was a 20‐year retrospective audit of clinical data from a regional paediatric diabetes service (June 2000–March 2021). The primary outcome was BMI standard deviation score (BMI SDS), whose trajectories from diagnosis were examined in association with demographic and clinical factors. Results: A total of 106 young people with T1D (56% male) were followed for a median of 8.3 years [Q1 = 6.1, Q3 = 11.0; maximum 15.1 years] and attended a median of 21 multidisciplinary clinic visits [Q1 = 12, Q3 = 30; range 1–56 visits]. In females, age at diagnosis modified the association between diabetes duration and BMI SDS (interaction p = 0.0009). Girls diagnosed at 4.0 years (age at diagnosis 25 th percentile for girls in our cohort) had no statistically significant change in BMI SDS over the first 5 years after diagnosis [−0.13 SDS (95% confidence interval [CI] −0.32 to 0.06); p = 0.18], while those diagnosed at 9.5 years (75 th percentile) experienced an increase of ≈0.39 SDS (0.08–0.70; p = 0.014). Among males, increasing age at diagnosis was associated with lower BMI SDS ( p < 0.0001), whereas there was no statistically significant association with diabetes duration ( p = 0.087). At any given duration, boys diagnosed at 11.1 years (age at diagnosis 75 th percentile for boys) had a BMI SDS approximately 0.70 lower (95% CI −1.02 to −0.45; p < 0.0001) than those diagnosed at 4.7 years (25 th percentile). Conclusions: We observed sex‐specific BMI trajectories in young people with T1D, with age at diagnosis exerting variable influences on BMI SDS trajectory in boys and girls. These findings support individualised T1D management strategies within multidisciplinary care.

  • Open Access

    Lifting the wellbeing of adolescents and young adults with type 1 diabetes: A feasibility study of the LIFT app

    by Anna Serlachius, Joanna McClintock, Anna Boggiss, Katie Babbott, Chloe Hudson, Paul Hofman, Hiran Thabrew, Alana Cavadino, Craig Jefferies, Ryan Paul, et al.


  • Open Access

    Screening Blind Spot: Missing Preterm Infants in the Detection of Congenital Hypothyroidism

    by Ashleigh Brown, Paul Hofman, Dianne Webster, Natasha Heather

    Congenital hypothyroidism (CH) is a critical condition in infancy where early detection is vital for optimal development. This study aimed to evaluate the sensitivity of Aotearoa New Zealand’s Newborn Metabolic Screening “Low Birth Weight” protocol for detecting CH in preterm infants. A 10-year audit was conducted on 2935 preterm infants (<2000 g or ≤34 weeks gestation) screened within NICUs or SCBUs in the Auckland region. The study assessed both screen-detected and clinically detected cases of CH. Data were collected from screening and clinical records to evaluate the sensitivity and reliability of the current protocol. The audit identified 19 cases of primary CH, with a 1:154 incidence. Thirteen cases met the criteria for inclusion in the audit. Just over half of the eligible cases (7/13) were screen-detected, while the remaining were detected clinically, suggesting limitations in screening sensitivity. The analysis revealed that the protocol missed permanent as well as transient cases, and that biochemical severity was not predictive of permanence. A revised screening protocol was developed and commenced in July 2024.


  • Open Access

    Iodine and other factors associated with fertility outcome following oil-soluble contrast medium hysterosalpingography: a prospective cohort study

    by Divya M. Mathews, Jane M. Peart, Robert G. Sim, Neil P. Johnson, Susannah O’sUllivan, José G B Derraik, Paul L. Hofman, Jos

    Objective: To examine factors associated with fertility following hysterosalpingography (HSG) using an oil-soluble contrast medium (OSCM).Design: In a prospective cohort study on 196 women undergoing OSCM HSG, we showed that iodine excess was almost universal (98%) and mild subclinical hypothyroidism was frequent (38%). Here, we report the analyses of secondary outcomes examining factors associated with the likelihood of pregnancy following the HSG.Setting: Auckland, New Zealand (2019–2021).Sample: 196 women with primary or secondary infertility who underwent OSCM HSG.Methods: Baseline and serial urine iodine concentrations (UIC) and thyroid function tests were measured over six months following the HSG. Pregnancy and treatment with levothyroxine during the study period were documented.Results: Following OSCM HSG, pregnancy rates were 49% in women aged <40 years (77/158) but considerably lower (16%) among those ≥40 years (6/38). Similarly, live birth rates were markedly lower in women ≥40 years (17%; 1/6) versus <40 years (73%; 56/77). 29% of participants were iodine deficient at baseline despite advice recommending iodine fortification. Following HSG, the likelihood of pregnancy in women with moderate iodine deficiency was 64% higher than in women with normal iodine levels (p=0.048). Among women aged 40 years. Iodine deficiency was relatively common in this cohort, and increased iodine levels from OSCM exposure may contribute to the improved fertility observed with this procedure. Trial registration: This study is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR: 12620000738921) https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620000738921.